Takeda Renews Deal with Proteome Sciences | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced Takeda Pharmaceuticals has extended a contract to use PS Biomarker Services for the development of mass spectrometry-based assays for disease-related proteins.

Financial and other terms of the deal were not disclosed.

In a statement, Proteome Sciences said it will apply its capabilities in the discovery and validation of peptide and protein biomarkers and in assay development for research covered by the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.